2947
Biomarker assays
~881 million
Protein data points generated
886
Publications listed on website
Scientists from Alnylam Pharamaceuticals used thirteen Olink Target 96 panels in a phase III clinical trial of the drug patisiran to treat the rare, progressively debilitating and ultimately fatal neurological disease, hereditary transthyretin-mediated (ATTRv) amyloidosis.
This study highlighted the value of large-scale protein biomarker discovery in drug development-related projects aimed at finding new disease biomarkers and looking for a molecular-level window into patient responses to therapeutics.
Interested in reading a more extensive summary of this study? Download the Olink eBook “Understand real-time human biology”.
Ticau et al., “Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis,” Neurology,
96:e412-e422, 2021.
2947
Biomarker assays
~881 million
Protein data points generated
886
Publications listed on website